Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema Attacks

Riedl MA, Cohn DM, Aygören-Pürsün E, Zanichelli A, Farkas H, Bernstein JA, Lumry WR, Smith MD, Yea CM, Audhya PK

2022 HAEi Global Leadership Workshop

Pharmacology of KVD824, an Investigational Drug for Prophylaxis of HAE

Grivcheva-Panovska V, Smith MD, Duckworth EJ, Hampton SL, Yea CM, Mutch P, Iverson M, Hansen E, Feener EP

BRADYKININ SYMPOSIUM

Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial

Longhurst HJ, Smith MD, Yea CM, Audhya PK

ASCIA 2022

Efficacy and Safety of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) in Adolescent and Adult Patients With Hereditary Angioedema: Phase 3 Trial Design

Aygören-Pürsün E, Zanichelli A, Cohn DM, Farkas H, Bernstein JA , Audhya PK, Smith MD, Yea CM, Lumry WR, Riedl MA, Maurer M

EAACI 2022

Novel Oral Small Molecule FXIIa Inhibitor Blocks Contact System Activation In Vivo

Allen C Clermont, Daniel Lee, Nivetha Murugesan, Hannah J Edwards, Stephen J Pethen, Edward J Duckworth, Sally L Hampton and Edward P Feener

EAACI 2022

Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Adult Volunteers and Patients With Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients

Smith MD, Rodgers T, Sharman J, Mutch P, Tachdjian R, Savic S, Farrell C

EAACI 2022

Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

Aygören-Pürsün E, Zanichelli A, Cohn DM, Audhya PK, Williams P, Yea CM, Smith MD

EAACI 2022

Oral factor XIIa inhibition blocks angiotensin converting enzyme inhibitor induced angioedema in mouse

Clermont AC, Murugesan N, Feener EP

KININ 2022

Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated kallikrein kinin system activation

Murugesan N, Lee DK, Duckworth EJ, Smith SA, Clermont AC, Hampton SL, Feener EP

KININ 2022

Oral sebetralstat (KVD900) provides rapid inhibition of the kallikrein kinin system in patients with hereditary angioedema

Duckworth EJ, Lee DK, Murugesan N, Rushbrooke L, Hampton SL, Smith M, Yea C, Audhya P, Feener EP

KININ 2022